


Tchaikapharma High Quality Medicines Inc.
Consolidated Statement of financial position
as of 30 June 2022


	30.06.2022	31.12.2021
Non-current assets	BGN'000	BGN'000
Property, plant and equipment	36,842	38,071
Intangible Assets and Goodwill	3,443	3,451
Trade receivables	5,276	5,276
Non-current assets	45,561	46,798
Inventories	8,990	11,342
Trade and other receivables	65,089	59,220
Current tax assets	-	40
Cash and cash equivalents	43	57
Current Assets	74,122	70,659
Assets	119,683	117,457
Issued capital	84,500	84,500
Statutory reserve	12,522	12,382
Retained earnings	4,384	1,937
Equity	101,406	98,819
<i>Equity Attributable to owners of the parent company</i>	<i>101,406</i>	<i>98,819</i>
<i>Non-controlling interest in equity</i>	<i>-</i>	<i>-</i>
Long term borrowings	1,499	1,717
Deferred tax liabilities	1,030	1,030
Non-current provisions for employee benefits	149	151
Non-current liabilities	2,678	2,898
Trade and other payables	4,519	4,721
Short term borrowings	10,648	10,771
Current tax liabilities	-	125
Current payables on Social Security and taxes	432	123
Current liabilities	15,599	15,740
Liabilities	18,277	18,638
Equity and liabilities	119,683	117,457

Date of preparation: 17.08.2022

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement of comprehensive income
as 30 June 2022


	30.06.2022	30.06.2021
	BGN'000	BGN'000
Revenue	22,668	22,302
Other income	313	21
Total income	22,981	22,323
Carrying amount of goods sold	(329)	(462)
Changes in inventories of finished products and work in progress	(626)	613
Materials and services	(14,294)	(14,467)
Personnel expenses	(2,769)	(2,691)
Depreciation / amortisation expenses	(1,825)	(2,037)
Other expenses	(198)	(282)
Finance income	23	11
Finance costs	(196)	(196)
Total expenses	(20,214)	(19,511)
Profit Loss before tax	2,767	2,812
Current tax expense income	(180)	(96)
Profit Loss	2,587	2,716
<i>Profit Loss attributable to owners of the parent company</i>	<i>2,587</i>	<i>2,716</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Other comprehensive income	2,587	2,716
<i>Profit Loss attributable to owners of the parent company</i>		
<i>Profit Loss attributable to non-controlling interests</i>		
Comprehensive income	2,587	2,716
<i>Profit Loss attributable to owners of the parent company</i>	<i>2,587</i>	<i>2,716</i>
<i>Profit Loss attributable to non-controlling interests</i>	<i>-</i>	<i>-</i>
Earnings per share / in BGN per 1 share /	0.03	0.03

Date of preparation: 17.08.2022

Executive director:


Biser Georgiev

Prepared by:


Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated Cash flow statement
as of 30 June 2022

	30.06.2022	30.06.2021
	BGN'000	BGN'000
Cash flows from operating activities		
Receipts from sales of goods and rendering of services	15,203	16,464
Payments to suppliers for goods and services	(8,615)	(11,089)
Payments to and on behalf of employees	(2,845)	(2,478)
Effect of exchange rate changes on cash and cash equivalents	(24)	
Income taxes paid classified as operating activities	(265)	(96)
Other cash payments from operating activities	(2,598)	(1,774)
Cash flows from used in operating activities	856	1,027
 Cash flows from investing activities		
Purchase of other longterm assets classified as investing activities	(507)	(731)
Cash flows from used in investing activities	(507)	(731)
 Cash flows from financial activities		
Dividends paid classified as financing activities	98	82
Proceeds from borrowings classified as financing activities	(97)	(185)
Repayments of borrowings classified as financing activities	(103)	(14)
Payments of lease liabilities classified as financing activities	(261)	(197)
Cash flows from used in financial activities	(363)	(314)
 Increase/Decrease in cash and cash equivalents	(14)	(18)
Cash and cash equivalents	57	64
Cash and cash equivalents	43	46

Date of preparation: 17.08.2022

Executive director:

Biser Georgiev

Prepared by:

Petya Moneva

Tchaikapharma High Quality Medicines Inc.
Consolidated statement on changes in equity
as of 30 June 2022

	Property plant and equipment revaluati on surplus	Other reserves	Retained earnings	Equity abstract	Equity Attributab le to owners of the parent company	Non- controllin g interest in equity	
	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	<i>BGN'000</i>	
Balance as of 01.01.2021	82,200	4,088	7,944	2,904	97,136	97,136	-
Profit Loss	-	-	-	1,396	1,396	1,396	-
Other comprehensive income	-	287	-	-	287	287	-
Comprehensive income	-	287	-	1,396	1,683	1,683	-
Increase/Decrease through appropriation of retained earnings	2,300	-	63	(2,363)	-	-	-
Total income expense	2,300	-	63	(2,363)	-	-	-
Balance as of 31.12.2021	84,500	4,375	8,007	1,937	98,819	98,819	-
Balance as of 01.01.2022	84,500	4,375	8,007	1,937	98,819	98,819	-
Profit Loss	-	-	-	2,587	2,587	2,587	-
Other comprehensive income	-	-	-	-	-	-	-
Comprehensive income	-	-	-	2,587	2,587	2,587	-
Increase/Decrease through appropriation of retained earnings	-	-	140	(140)	-	-	-
Total income expense	-	-	140	(140)	-	-	-
Balance as of 30.06.2022	84,500	4,375	8,147	4,684	101,406	101,406	-


Date of preparation: 17.08.2022

Executive director:



Biser Georgiev

Prepared by:



Petya Moneva